Solvay Pharmaceuticals signs additional agreement to get maximum global expansion for Androgel
Solvay Pharmaceuticals announced the signing of additional agreements for important geographical expansions to one of its top selling products AndroGel® with the pharmaceutical company Besins International. AndroGel® is used in Testosterone Replacement Therapy (TRT) and one of Solvay's solid performers; according to Solvay in 2005 sales exceeded EUR 235 million Euro in the USA, Canada and Germany.
Solvay Pharmaceuticals now acquires exclusive distribution rights for Latin America (including Brazil and Argentina), for several countries in Asia and for all African countries. Semi-exclusive rights are now acquired for five additional European countries (France, Belgium, UK, Spain, Greece).
Most read news
Other news from the department research and development

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
LANXESS: Price adjustment for engineering plastics
Electrochemistry
